Shaun Barnabas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shaun Barnabas has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Mark Frederic Cotton
Stellenbosch University, South Africa
6 shared publications - Jo Ann S Passmore
Department of Pathology, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa
5 shared publications - Linda-Gail Bekker
Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
5 shared publications - Smritee Dabee
Institute of Infectious Disease and Molecular Medicine (IDM), Division of Medical Virology, Dept. Pathology, University of Cape Town, Cape Town, South Africa
5 shared publications - Heather Berryl Jaspan
Department of Pathology, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa
4 shared publications - Bart Versteeg
Knowledge Institute of the Dutch Association of Medical Specialists, Utrecht, Netherlands
3 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e103274
Dosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35)
Background: Young children with exposure to or infection with Mycobacterium tuberculosis are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2 years and in children living with HIV. Objective: This protocol describes Tuberculosis Trials Consortium (TBTC) Study 35, which aims to establish practical age- and weight-banded rifapentine doses for 3HP in children aged 0 to 12 years, including children younger than 2 years, and children living with HIV, while assessing safety, tolerability, palatability, and acceptability. Methods: TBTC Study 35 was a phase I/II, open-label, multisite, single-arm, exposure-controlled dose-finding and safety study of 3HP in children aged 0 to 12 years, including children living with HIV. Novel water-dispersible rifapentine and isoniazid formulations were used. Building on TBTC Study 26 data, initial rifapentine doses were selected, and nonlinear mixed-effects modeling was used to analyze the pharmacokinetic data and evaluate subsequent rifapentine doses. Safety was monitored throughout the 12-week treatment period and 12-week posttreatment follow-up. Results: Data collection began with the first recruitment in November 2019. The last participant was enrolled in December 2023, and participant follow-up and data collection were completed in May 2024. As of now, 69 participants were enrolled. The trial was funded throughout this time period. Data analysis is ongoing, and trial results are expected to be disseminated in 2026. Conclusions: TBTC Study 35 is expected to provide pharmacokinetic and safety data to inform practical pediatric 3HP dosing recommendations, including for children younger than 2 years and children living with HIV.
- 30 September 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e103274
Open AccessDosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35)
Background: Young children with exposure to or infection with Mycobacterium tuberculosis are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2 years and in children living with HIV. Objective: This protocol describes Tuberculosis Trials Consortium (TBTC) Study 35, which aims to establish practical age- and weight-banded rifapentine doses for 3HP in children aged 0 to 12 years, including children younger than 2 years, and children living with HIV, while assessing safety, tolerability, palatability, and acceptability. Methods: TBTC Study 35 was a phase I/II, open-label, multisite, single-arm, exposure-controlled dose-finding and safety study of 3HP in children aged 0 to 12 years, including children living with HIV. Novel water-dispersible rifapentine and isoniazid formulations were used. Building on TBTC Study 26 data, initial rifapentine doses were selected, and nonlinear mixed-effects modeling was used to analyze the pharmacokinetic data and evaluate subsequent rifapentine doses. Safety was monitored throughout the 12-week treatment period and 12-week posttreatment follow-up. Results: Data collection began with the first recruitment in November 2019. The last participant was enrolled in December 2023, and participant follow-up and data collection were completed in May 2024. As of now, 69 participants were enrolled. The trial was funded throughout this time period. Data analysis is ongoing, and trial results are expected to be disseminated in 2026. Conclusions: TBTC Study 35 is expected to provide pharmacokinetic and safety data to inform practical pediatric 3HP dosing recommendations, including for children younger than 2 years and children living with HIV.
- Open Access
- 29 January 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e957-e962
High Prevalence and Genotypic Diversity of Persistent Chlamydia Trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities
Chlamydia trachomatis (CT) is the most common sexually transmitted bacterial infection globally, significantly affecting adolescent girls and young women (AGYW) in South Africa. This study investigated CT prevalence and genotypic diversity among 298 AGYW from Cape Town and Johannesburg, revealing an overall prevalence of 29.5%. Prevalence was higher in Cape Town (41.6%) compared to Johannesburg (17.4%; P < .0001). Genetic analysis identified 34 sequence types, including 15 novel variants. Longitudinal data highlighted frequent reinfections or persistent infections despite treatment. These findings underscore the importance of addressing CT's genetic diversity for improved reproductive health strategies and vaccine development.
- 29 January 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (4) , e957-e962
Open AccessHigh Prevalence and Genotypic Diversity of Persistent Chlamydia Trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities
Chlamydia trachomatis (CT) is the most common sexually transmitted bacterial infection globally, significantly affecting adolescent girls and young women (AGYW) in South Africa. This study investigated CT prevalence and genotypic diversity among 298 AGYW from Cape Town and Johannesburg, revealing an overall prevalence of 29.5%. Prevalence was higher in Cape Town (41.6%) compared to Johannesburg (17.4%; P < .0001). Genetic analysis identified 34 sequence types, including 15 novel variants. Longitudinal data highlighted frequent reinfections or persistent infections despite treatment. These findings underscore the importance of addressing CT's genetic diversity for improved reproductive health strategies and vaccine development.
- Open Access
- 3 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e290-e300
Chlamydia trachomatis -specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women
Background: Chlamydia trachomatis remains the most prevalent bacterial sexually transmitted infection worldwide, disproportionately affecting adolescent girls and young women (AGYW). Vaccine development is hindered by a limited understanding of protective immunity, particularly in the context of multiple exposures and immunopathology. Methods: We characterized mucosal inflammation and systemic immune responses to C. trachomatis in South African AGYW (n = 145), stratified by exposure history based on nucleic acid amplification testing (NAAT) and serology (Ab). Specifically, cervicovaginal cytokines, cervical T cell activation, and C. trachomatis-specific CD4+ T cell responses were assessed. Results: A NAAT+/Ab + status, signifying untreated/recurrent infection, was associated with increased cervical T cell activation. These women all had detectable C. trachomatis-specific CD4+ T cells in blood; however, the magnitude of the response was 2.4-fold lower than in NAAT−/Ab + (cleared infection) or NAAT+/Ab− (primary infection) groups. C. trachomatis-specific multifunctional CD4+ T cells were highest in NAAT−/Ab + women, and nearly absent in those who were NAAT+/Ab +. Notably, systemic C. trachomatis-specific Th1 responses were overall inversely correlated with genital tract concentrations of inflammatory cytokines, including IL-1β, TNF, and IL-17A. Conclusions: Both the magnitude and quality of the systemic CD4+ T cell responses are critical components of protective immunity to C. trachomatis and may limit mucosal immunopathology, informing vaccine strategies in high-risk populations.
- 3 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e290-e300
Open AccessChlamydia trachomatis -specific T Cell Immunity Reflects Widespread Exposure in South African Adolescents and Young Women
Background: Chlamydia trachomatis remains the most prevalent bacterial sexually transmitted infection worldwide, disproportionately affecting adolescent girls and young women (AGYW). Vaccine development is hindered by a limited understanding of protective immunity, particularly in the context of multiple exposures and immunopathology. Methods: We characterized mucosal inflammation and systemic immune responses to C. trachomatis in South African AGYW (n = 145), stratified by exposure history based on nucleic acid amplification testing (NAAT) and serology (Ab). Specifically, cervicovaginal cytokines, cervical T cell activation, and C. trachomatis-specific CD4+ T cell responses were assessed. Results: A NAAT+/Ab + status, signifying untreated/recurrent infection, was associated with increased cervical T cell activation. These women all had detectable C. trachomatis-specific CD4+ T cells in blood; however, the magnitude of the response was 2.4-fold lower than in NAAT−/Ab + (cleared infection) or NAAT+/Ab− (primary infection) groups. C. trachomatis-specific multifunctional CD4+ T cells were highest in NAAT−/Ab + women, and nearly absent in those who were NAAT+/Ab +. Notably, systemic C. trachomatis-specific Th1 responses were overall inversely correlated with genital tract concentrations of inflammatory cytokines, including IL-1β, TNF, and IL-17A. Conclusions: Both the magnitude and quality of the systemic CD4+ T cell responses are critical components of protective immunity to C. trachomatis and may limit mucosal immunopathology, informing vaccine strategies in high-risk populations.
- 14 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (2S) , S85-S89
Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective
Background: Maternal immunization is a valuable public health measure protecting the mother, fetus and newborn infant against targeted infectious diseases, playing an integral role in pregnancy outcomes. Limited literature exists from the African continent pertaining to the timing and utilization of maternal influenza and tetanus toxoid immunization. Maintaining high vaccine coverage is imperative for successful disease control, highlighting the importance of continued maternal immunization. We aimed to describe the utilization and timing of influenza and tetanus vaccinations during pregnancy, within South African publicly financed antenatal care facilities. Methods: A secondary analysis was conducted of clinical antenatal, vaccination and delivery data collected during a retrospective review of randomly selected maternity charts of women who delivered between July 2018 and June 2019 in Johannesburg and Cape Town, South Africa. Results: Influenza vaccination uptake within the sampled population was 16.6% (806/4851), with significantly higher odds of influenza vaccination in women 21-30 years of age and women with ≥6 antenatal care visits. Of 7031 (99.0% of the population) women who received at least 1 dose of tetanus toxoid–containing vaccine (TTCV), 39.2% (2759) received 1 dose; 51.0% (3590) received 2 and 9.7% (682) received 3 doses in their index pregnancy. Conculsions: Antenatal facilities are ideally suited to administer vaccines to pregnant women; however, targeted educational campaigns and immunization promotion by antenatal staff will improve maternal influenza immunization coverage. There is high utilization of TTCV in South Africa, with over 99% of women receiving at least 1 dose of TTCV, which is encouraging, especially considering that South Africa is implementing a single dose of a combination tetanus-diphtheria-acellular pertussis vaccine to replace tetanus toxoid (TT) in pregnancy.
- 14 February 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (2S) , S85-S89
Vaccine Utilization and Timing of Administration in Pregnant Women: A South African Perspective
Background: Maternal immunization is a valuable public health measure protecting the mother, fetus and newborn infant against targeted infectious diseases, playing an integral role in pregnancy outcomes. Limited literature exists from the African continent pertaining to the timing and utilization of maternal influenza and tetanus toxoid immunization. Maintaining high vaccine coverage is imperative for successful disease control, highlighting the importance of continued maternal immunization. We aimed to describe the utilization and timing of influenza and tetanus vaccinations during pregnancy, within South African publicly financed antenatal care facilities. Methods: A secondary analysis was conducted of clinical antenatal, vaccination and delivery data collected during a retrospective review of randomly selected maternity charts of women who delivered between July 2018 and June 2019 in Johannesburg and Cape Town, South Africa. Results: Influenza vaccination uptake within the sampled population was 16.6% (806/4851), with significantly higher odds of influenza vaccination in women 21-30 years of age and women with ≥6 antenatal care visits. Of 7031 (99.0% of the population) women who received at least 1 dose of tetanus toxoid–containing vaccine (TTCV), 39.2% (2759) received 1 dose; 51.0% (3590) received 2 and 9.7% (682) received 3 doses in their index pregnancy. Conculsions: Antenatal facilities are ideally suited to administer vaccines to pregnant women; however, targeted educational campaigns and immunization promotion by antenatal staff will improve maternal influenza immunization coverage. There is high utilization of TTCV in South Africa, with over 99% of women receiving at least 1 dose of TTCV, which is encouraging, especially considering that South Africa is implementing a single dose of a combination tetanus-diphtheria-acellular pertussis vaccine to replace tetanus toxoid (TT) in pregnancy.
- Open Access
Cervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with Chlamydia trachomatis infections
Background: Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by Chlamydia trachomatis (CT) infections, a leading cause of pelvic inflammatory disease (PID), infertility, and increased HIV susceptibility. CT-induced genital inflammation disrupts mucosal barriers and activates HIV target cells, compounding reproductive and immunological risks. We investigated the impact of CT infection in AGYW from two South African regions, focusing on genital inflammation and immune activation. Methods: An observational cohort of 298 sexually active AGYW (16–22 years) from Cape Town and Johannesburg was enrolled. Participants in Johannesburg attended a single study visit, while those in Cape Town were followed longitudinally for up to three visits over 6–8 months. Cytokine profiling of cervicovaginal samples assessed inflammatory responses, while cervical cytobrush-derived CD4+ T cells were analyzed for CD38, Ki67 and CCR5 expression. CT ompA genotyping examined strain diversity. Results: CT prevalence was 2.4 times higher in Cape Town (41.6%) than in Johannesburg (17.4%). Infection with CT led to an upregulation of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, with a stronger inflammatory response observed in Johannesburg. Genotypic analysis revealed regional variation: genovar D, predominant in Cape Town, was associated with lower IFN-γ concentrations, whereas genovar E, more common in Johannesburg, was associated with higher IFN-γ levels. AGYW who experienced CT infection across multiple study visits did not exhibit elevated genital tract cytokine levels compared to those with a single infection. However, they did show an increase in activated and proliferating cervical CD4+ T cells, which may contribute to heightened HIV susceptibility. Conclusions: CT genotypic diversity and regional variation are associated with differences in immune responses in AGYW, alongside important contributions from host immune history. These findings support the need for integrated sexual health services and inform future regionally relevant vaccine strategies.
Open AccessCervicovaginal inflammation and HIV target cell activation in adolescent girls and young women with Chlamydia trachomatis infections
Background: Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by Chlamydia trachomatis (CT) infections, a leading cause of pelvic inflammatory disease (PID), infertility, and increased HIV susceptibility. CT-induced genital inflammation disrupts mucosal barriers and activates HIV target cells, compounding reproductive and immunological risks. We investigated the impact of CT infection in AGYW from two South African regions, focusing on genital inflammation and immune activation. Methods: An observational cohort of 298 sexually active AGYW (16–22 years) from Cape Town and Johannesburg was enrolled. Participants in Johannesburg attended a single study visit, while those in Cape Town were followed longitudinally for up to three visits over 6–8 months. Cytokine profiling of cervicovaginal samples assessed inflammatory responses, while cervical cytobrush-derived CD4+ T cells were analyzed for CD38, Ki67 and CCR5 expression. CT ompA genotyping examined strain diversity. Results: CT prevalence was 2.4 times higher in Cape Town (41.6%) than in Johannesburg (17.4%). Infection with CT led to an upregulation of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, with a stronger inflammatory response observed in Johannesburg. Genotypic analysis revealed regional variation: genovar D, predominant in Cape Town, was associated with lower IFN-γ concentrations, whereas genovar E, more common in Johannesburg, was associated with higher IFN-γ levels. AGYW who experienced CT infection across multiple study visits did not exhibit elevated genital tract cytokine levels compared to those with a single infection. However, they did show an increase in activated and proliferating cervical CD4+ T cells, which may contribute to heightened HIV susceptibility. Conclusions: CT genotypic diversity and regional variation are associated with differences in immune responses in AGYW, alongside important contributions from host immune history. These findings support the need for integrated sexual health services and inform future regionally relevant vaccine strategies.
- Open Access
High Prevalence and Genotypic Diversity of Persistent Chlamydia trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities
Chlamydia trachomatis (CT) is the most common sexually transmitted bacterial infection globally, significantly affecting adolescent girls and young women (AGYW) in South Africa. This study investigated CT prevalence and genotypic diversity among 298 AGYW from Cape Town and Johannesburg, revealing an overall prevalence of 29.5%. Prevalence was higher in Cape Town (41.6%) compared to Johannesburg (17.4%; pChlamydia trachomatis infection is highly prevalent and asymptomatic among South African adolescent girls and young women, with marked regional and genotypic diversity. Frequent persistence or reinfection highlights the need for improved screening, surveillance, and targeted prevention strategies.
Open AccessHigh Prevalence and Genotypic Diversity of Persistent Chlamydia trachomatis Infections Among South African Adolescent Girls and Young Women: A Tale of Two Cities
Chlamydia trachomatis (CT) is the most common sexually transmitted bacterial infection globally, significantly affecting adolescent girls and young women (AGYW) in South Africa. This study investigated CT prevalence and genotypic diversity among 298 AGYW from Cape Town and Johannesburg, revealing an overall prevalence of 29.5%. Prevalence was higher in Cape Town (41.6%) compared to Johannesburg (17.4%; pChlamydia trachomatis infection is highly prevalent and asymptomatic among South African adolescent girls and young women, with marked regional and genotypic diversity. Frequent persistence or reinfection highlights the need for improved screening, surveillance, and targeted prevention strategies.
- 26 March 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , 669-674
Cardiometabolic Risk Profiles of Adolescents Living With Perinatally Acquired HIV in South Africa
Background: We assessed the Pathological Determinants of Atherosclerosis in Youth (PDAY) score and other potential cardiovascular disease risk factors in adolescents previously enrolled in the Children with HIV Early antiRetroviral (CHER) and International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1060 clinical trials. Methods: Coronary artery and abdominal aorta (AA) PDAY scores were calculated for 56 participants over 15 years of age using a weighted combination of dyslipidemia, cigarette smoking, hypertension, obesity, and hyperglycemia. A PDAY score ≥1 is associated with early atherosclerosis. Results: Fifty-six participants were enrolled: 46 (82.1%) on a single-tablet regimen of tenofovir disoproxil fumarate, lamivudine and dolutegravir. Median time on antiretroviral therapy was 15.8 [interquartile range (IQR): 15.8–16.5] years and median time on dolutegravir was 14 (IQR: 10.0–19.0) months. Fasting median high-density lipoprotein cholesterol was 20.1 mg/dL (IQR: 16.0–23.7) and median non-high-density lipoprotein cholesterol was 38.3 mg/dL (IQR: 30.8–44.3). The median systolic blood pressure was 115 mm Hg (IQR: 107–121). Median body mass index was 21.3 kg/m2 (IQR: 19.5–24.7) and median fasted serum glucose was 82.0 mg/dL (IQR: 75.7–87.3). Only 1 (2%) participant smoked cigarettes, but 5 (9%) smoked hookah pipe and 26 (46.4%) smoked cannabis. Thirty-one (55.4%) participants had coronary artery PDAY scores ≥1 and 33 (58.9%) had AA PDAY scores ≥1. Age was associated with an AA PDAY score ≥1 (P = 0.02) with a 0.06 increase in AA PDAY score for every month of age (95% confidence interval: 0.01–0.12, P = 0.01). Conclusions: Adolescents with perinatally acquired HIV appear at risk for cardiovascular disease. Specific tools for monitoring this risk are needed to institute appropriate preventive interventions.
- 26 March 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (7) , 669-674
Cardiometabolic Risk Profiles of Adolescents Living With Perinatally Acquired HIV in South Africa
Background: We assessed the Pathological Determinants of Atherosclerosis in Youth (PDAY) score and other potential cardiovascular disease risk factors in adolescents previously enrolled in the Children with HIV Early antiRetroviral (CHER) and International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1060 clinical trials. Methods: Coronary artery and abdominal aorta (AA) PDAY scores were calculated for 56 participants over 15 years of age using a weighted combination of dyslipidemia, cigarette smoking, hypertension, obesity, and hyperglycemia. A PDAY score ≥1 is associated with early atherosclerosis. Results: Fifty-six participants were enrolled: 46 (82.1%) on a single-tablet regimen of tenofovir disoproxil fumarate, lamivudine and dolutegravir. Median time on antiretroviral therapy was 15.8 [interquartile range (IQR): 15.8–16.5] years and median time on dolutegravir was 14 (IQR: 10.0–19.0) months. Fasting median high-density lipoprotein cholesterol was 20.1 mg/dL (IQR: 16.0–23.7) and median non-high-density lipoprotein cholesterol was 38.3 mg/dL (IQR: 30.8–44.3). The median systolic blood pressure was 115 mm Hg (IQR: 107–121). Median body mass index was 21.3 kg/m2 (IQR: 19.5–24.7) and median fasted serum glucose was 82.0 mg/dL (IQR: 75.7–87.3). Only 1 (2%) participant smoked cigarettes, but 5 (9%) smoked hookah pipe and 26 (46.4%) smoked cannabis. Thirty-one (55.4%) participants had coronary artery PDAY scores ≥1 and 33 (58.9%) had AA PDAY scores ≥1. Age was associated with an AA PDAY score ≥1 (P = 0.02) with a 0.06 increase in AA PDAY score for every month of age (95% confidence interval: 0.01–0.12, P = 0.01). Conclusions: Adolescents with perinatally acquired HIV appear at risk for cardiovascular disease. Specific tools for monitoring this risk are needed to institute appropriate preventive interventions.
- Open Access
Obstetric and neonatal outcomes in South Africa
- Open Access
- 1 January 2024
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 39 (1) , 3
SARS-CoV-2 antibodies in adolescents living with perinatally acquired HIV
Data on children and adolescents with HIV and coronavirus disease 2019 (COVID-19) co-infection are limited. Clinical and antibody data related to COVID-19 infection in adolescents living with perinatally acquired HIV (ALPHIV) and originally enrolled in the Children with HIV Early Antiretroviral Therapy (CHER) study were collected. We present a descriptive analysis of 53 ALPHIV who were tested for anti-SARS-CoV-2 antibodies. Just over half (53%) of the adolescents tested had positive anti-SARS-CoV-2 antibodies with only one participant describing a prior history of possible symptomatic infection. Contribution: The study contributes to the understanding of SARS-CoV-2 infection and vaccination practices in HIV-positive adolescents.
- 1 January 2024
- Published by AOSIS in Southern African Journal of Infectious Diseases
- Vol. 39 (1) , 3
Open AccessSARS-CoV-2 antibodies in adolescents living with perinatally acquired HIV
Data on children and adolescents with HIV and coronavirus disease 2019 (COVID-19) co-infection are limited. Clinical and antibody data related to COVID-19 infection in adolescents living with perinatally acquired HIV (ALPHIV) and originally enrolled in the Children with HIV Early Antiretroviral Therapy (CHER) study were collected. We present a descriptive analysis of 53 ALPHIV who were tested for anti-SARS-CoV-2 antibodies. Just over half (53%) of the adolescents tested had positive anti-SARS-CoV-2 antibodies with only one participant describing a prior history of possible symptomatic infection. Contribution: The study contributes to the understanding of SARS-CoV-2 infection and vaccination practices in HIV-positive adolescents.
- Open Access
- 16 April 2023
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 36 (3) , 819-832
Associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children: a two‐way factorial case–control study
Background: Human immunodeficiency virus (HIV) and iron deficiency (ID) affect many African children. Both HIV and iron status interact with gut microbiota composition and related biomarkers. The study's aim was to determine the associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children.Methods: In this two‐way factorial case–control study, 8‐ to 13‐year‐old children were enrolled into four groups based on their HIV and iron status: (1) With HIV (HIV+) and ID (n = 43), (2) HIV+ and iron‐sufficient nonanaemic (n = 41), (3) without HIV (HIV−) and ID (n = 44) and (4) HIV− and iron‐sufficient nonanaemic (n = 38). HIV+ children were virally suppressed (p = 0.007). I‐FABP did not significantly differ by HIV or iron status. ART‐treated HIV (redundancy analysis [RDA] R2 = 0.009, p = 0.029) and age (RDA R2 = 0.013 p = 0.004) explained the variance in the gut microbiota across the four groups. Probabilistic models showed that the relative abundance of the butyrate‐producing genera Anaerostipes and Anaerotruncus was lower in ID versus iron‐sufficient children. Fusicatenibacter was lower in HIV+ and in ID children versus their respective counterparts. The prevalence of the inflammation‐associated genus Megamonas was 42% higher in children with both HIV and ID versus HIV− and iron‐sufficient nonanaemic counterparts.Conclusions: In our sample of 8‐ to 13‐year‐old virally suppressed HIV+ and HIV− children with or without ID, ID was associated with increased gut inflammation and changes in the relative abundance of specific microbiota. Moreover, in HIV+ children, ID had a cumulative effect that further shifted the gut microbiota to an unfavourable composition.
- 16 April 2023
- Published by Wiley in Journal of Human Nutrition and Dietetics
- Vol. 36 (3) , 819-832
Open AccessAssociations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children: a two‐way factorial case–control study
Background: Human immunodeficiency virus (HIV) and iron deficiency (ID) affect many African children. Both HIV and iron status interact with gut microbiota composition and related biomarkers. The study's aim was to determine the associations of HIV and iron status with gut microbiota composition, gut inflammation and gut integrity in South African school‐age children.Methods: In this two‐way factorial case–control study, 8‐ to 13‐year‐old children were enrolled into four groups based on their HIV and iron status: (1) With HIV (HIV+) and ID (n = 43), (2) HIV+ and iron‐sufficient nonanaemic (n = 41), (3) without HIV (HIV−) and ID (n = 44) and (4) HIV− and iron‐sufficient nonanaemic (n = 38). HIV+ children were virally suppressed (p = 0.007). I‐FABP did not significantly differ by HIV or iron status. ART‐treated HIV (redundancy analysis [RDA] R2 = 0.009, p = 0.029) and age (RDA R2 = 0.013 p = 0.004) explained the variance in the gut microbiota across the four groups. Probabilistic models showed that the relative abundance of the butyrate‐producing genera Anaerostipes and Anaerotruncus was lower in ID versus iron‐sufficient children. Fusicatenibacter was lower in HIV+ and in ID children versus their respective counterparts. The prevalence of the inflammation‐associated genus Megamonas was 42% higher in children with both HIV and ID versus HIV− and iron‐sufficient nonanaemic counterparts.Conclusions: In our sample of 8‐ to 13‐year‐old virally suppressed HIV+ and HIV− children with or without ID, ID was associated with increased gut inflammation and changes in the relative abundance of specific microbiota. Moreover, in HIV+ children, ID had a cumulative effect that further shifted the gut microbiota to an unfavourable composition.